TSE:APS Aptose Biosciences (APS) Stock Price, News & Analysis C$0.77 -0.02 (-2.53%) (As of 07/26/2024 ET) Add Compare Share Share Today's RangeC$0.77▼C$0.7950-Day RangeC$0.77▼C$1.6152-Week RangeC$0.77▼C$6.90Volume4,031 shsAverage Volume8,526 shsMarket CapitalizationC$12.56 millionP/E RatioN/ADividend Yield0.39%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades Get Aptose Biosciences alerts: Email Address Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Aptose Biosciences Stock (TSE:APS)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APS Stock News HeadlinesJuly 25 at 8:53 AM | theglobeandmail.comAptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (APS)July 20, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Announces Receipt of Deficiency Notice from NasdaqJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 17, 2024 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Thursday (APS)May 17, 2024 | markets.businessinsider.comBuy Rating for Aptose Biosciences on Tuspetinib’s Promising AML Study and Synergistic PotentialMay 15, 2024 | finanznachrichten.deAptose Biosciences, Inc.: Aptose Reports Results for the First Quarter 2024May 14, 2024 | msn.comAPTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024May 14, 2024 | sfgate.comAptose Biosciences: Q1 Earnings SnapshotJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 14, 2024 | finance.yahoo.comAptose Biosciences Q1 Net Loss Falls, on Lower ExpensesMarch 28, 2024 | seekingalpha.comAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | benzinga.comAptose Biosciences's Earnings: A PreviewJanuary 31, 2024 | finance.yahoo.comAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment OptionDecember 20, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc flat on Wednesday (APS)December 9, 2023 | finance.yahoo.comAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingNovember 30, 2023 | finance.yahoo.comAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleNovember 10, 2023 | finance.yahoo.comAptose Biosciences Inc. (NASDAQ:APTO) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comAptose Reports Results for the Third Quarter 2023See More Headlines Receive APS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:APS CUSIPN/A CIKN/A Webaptose.com Phone+1-647-4799828FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($10.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-51,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-293.95% Return on Assets-102.23% Debt Debt-to-Equity Ratio14.27 Current Ratio0.78 Quick Ratio5.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.48 per share Price / Cash Flow1.60 Book ValueC($0.37) per share Price / Book-2.08Miscellaneous Outstanding Shares16,310,000Free FloatN/AMarket CapC$12.56 million OptionableNot Optionable Beta1.47 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsHelix BioPharmaTSE:HBPEmerald Health TherapeuticsCVE:EMHCovalon TechnologiesCVE:COVProMIS NeurosciencesTSE:PMNSmall PharmaCVE:DMTView All Competitors APS Stock Analysis - Frequently Asked Questions How have APS shares performed this year? Aptose Biosciences' stock was trading at C$3.35 at the beginning of 2024. Since then, APS shares have decreased by 77.0% and is now trading at C$0.77. View the best growth stocks for 2024 here. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (TSE:APS) posted its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.14. How do I buy shares of Aptose Biosciences? Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE) and AltaGas (ALA). This page (TSE:APS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.